Alkylating
Navigation Links
Alkylating in Medical News
The Cancer Genome Atlas reports first results, Johns Hopkins Kimmel Cancer Center collaborates
... makes brain cancer cells more responsive to anticancer drugs known as alkylating agents. While brain cancer patients with the MGMT alteration respond better to the commonly-used alkylating agent temozolomide, the new TCGA research found that treatment also ...... tumor lysis syndrome, skin reactions, and other malignancies. TREANDA has a unique chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component. Though the exact mechanism of action of TREANDA remains unknown, TREANDA may act in two distinct ...
New Report Just Published: World Multiple Myeloma Therapeutics Market Report
... Infusion II-35 Hematological Cancer Drug Classes II-35 Hypomethylating Agents & Antimetabolites II-35 Bisphosphonates II-36 alkylating Agents and DNA-Damaging Agents II-36 DNA-Repair Enzyme Inhibitors II-36 Histone Deacetylase Inhibitor II-36 Immunomodulators II-36 ...Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009
... of 50. TRC102 is a small molecule inhibitor of base excision repair that improves the therapeutic index of commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an i.v. agent in ...... cycle, for up to eight cycles. About TREANDA TREANDA is a novel treatment with a unique chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component. Though the exact mechanism of action of TREANDA remains unknown, TREANDA may act in two distinct ...
... cycle, for up to eight cycles. About TREANDA TREANDA is a novel treatment with a unique chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component. Though the exact mechanism of action of TREANDA remains unknown, TREANDA may act in two distinct ...
Vion Reports 2008 Second Quarter and Six-Month Results
... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...
... developed by Abbott researchers to prevent DNA repair in cancer cells and increase the effectiveness of common cancer therapies such as radiation and alkylating agents. ABT-888 completed a Phase 0 trial for patients with refractory solid tumors and lymphoid malignancies, and has entered several Phase I ...
Vion Pharmaceuticals to Appeal Nasdaq Delisting
... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...Alkylating in Medical Technology
TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
... on cancer stem cells. TRC102 is a small molecule inhibitor of base excision repair that reverses resistance to commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an intravenous agent ...... conjugate was well-tolerated in cynomolgous monkeys and mouse models. The critical role of cleavable linkers for minor groove binding alkylating agent (MGBA) based antibody-drug conjugates (Abstract #1722) The effectiveness of a cleavable linker over a non-cleavable linker when used with ...
... Campath was initially approved in 2001 under accelerated approval regulations for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Campath was developed by Genzyme Corporation. Campath is marketed in the U.S. by Bayer HealthCare ...
... Campath was initially approved in 2001 under accelerated approval regulations for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Campath was developed by Genzyme Corporation. Campath is marketed in the U.S. by Bayer HealthCare ...
... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...
... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...
... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...
... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...
... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...
... and apoptosis. In preclinical in vitro and animal model studies it shows activity against human tumors including melanoma and is synergistic with alkylating agents including dacarbazine. Fifty (50) patients were treated with Amplimexon at MTD (maximum tolerated dose) during the Phase II portion of the ...
Alkylating in Medical Dictionary
... of myeloablative therapy with autologous bone marrow or peripheral blood stem cell support, as well as conventional chemotherapy -containing alkylating agents. The TdT stain differentiates between acute lymphoblastic leukemia (cells stain positive) and acute myelogenous leukemia (cells stain ...
... anemia and/or thrombocytopenia can occur in patients with any stage of CLL.[9] Initial therapy involves corticosteroids with or without alkylating agents (fludarabine can worsen the hemolytic anemia ). Auto immune hemolytic anemia without another underlying cause Drug -induced ...
... anemia and/or thrombocytopenia can occur in patients with any stage of CLL.[9] Initial therapy involves corticosteroids with or without alkylating agents (fludarabine can worsen the hemolytic anemia ). Auto immune hemolytic anemia without another underlying cause Drug -induced ...
... observation with treatment of infectious, hemorrhagic , or immunologic complications to a variety of therapeutic options, including steroids, alkylating agents, p urine analogs, ... Mesnex (mesna) tablets, 400 mg Indication: use as a prophylactic agent in reducing the incidence of ...
... anemia and/or thrombocytopenia can occur in patients with any stage of CLL.[9] Initial therapy involves corticosteroids with or without alkylating agents (fludarabine can worsen the hemolytic anemia ). Auto immune hemolytic anemia . Occurs when the body produces antibodies that coat red ...
... structure to the nose, ears, larynx , and other parts of the body. carzelesin An anti cancer drug that belongs to the family of drugs called alkylating agents. Pain in the bones or joints Swelling or discomfort in the abdomen (from an enlarged spleen ) Swollen lymph node s, especially in ...
... is a cancer ; sometimes those are just normal changes in the nail color. Dacarbazine (da-KAR-ba-zeen) belongs to the group of medicines called alkylating agents. It is used to treat cancer of the lymph system and malignant melanoma (a type of skin cancer ). CONGENITAL GIANT PIGM ENT ED ...
... by activating signaling pathways that regulate the cell cycle, DNA repair, and apo ptosis . Temodar (temozolomide) capsules An oral cyto toxic alkylating agent, one of a class of compounds known as imidazotetrazines. Indication: treatment of adult patients with refractory an aplastic astrocytoma, ...
... anemia and/or thrombocytopenia can occur in patients with any stage of CLL.[9] Initial therapy involves corticosteroids with or without alkylating agents (fludarabine can worsen the hemolytic anemia ). Auto immune hemolytic anemia without another underlying cause Drug -induced ...
... anemia and/or thrombocytopenia can occur in patients with any stage of CLL.[9] Initial therapy involves corticosteroids with or without alkylating agents (fludarabine can worsen the hemolytic anemia ). Auto immune hemolytic anemia without another underlying cause Drug -induced ...
... observation with treatment of infectious, hemorrhagic , or immunologic complications to a variety of therapeutic options, including steroids, alkylating agents, p urine analogs, ... Mesnex (mesna) tablets, 400 mg Indication: use as a prophylactic agent in reducing the incidence of ...
... anemia and/or thrombocytopenia can occur in patients with any stage of CLL.[9] Initial therapy involves corticosteroids with or without alkylating agents (fludarabine can worsen the hemolytic anemia ). Auto immune hemolytic anemia . Occurs when the body produces antibodies that coat red ...
... structure to the nose, ears, larynx , and other parts of the body. carzelesin An anti cancer drug that belongs to the family of drugs called alkylating agents. Pain in the bones or joints Swelling or discomfort in the abdomen (from an enlarged spleen ) Swollen lymph node s, especially in ...
... is a cancer ; sometimes those are just normal changes in the nail color. Dacarbazine (da-KAR-ba-zeen) belongs to the group of medicines called alkylating agents. It is used to treat cancer of the lymph system and malignant melanoma (a type of skin cancer ). CONGENITAL GIANT PIGM ENT ED ...
... by activating signaling pathways that regulate the cell cycle, DNA repair, and apo ptosis . Temodar (temozolomide) capsules An oral cyto toxic alkylating agent, one of a class of compounds known as imidazotetrazines. Indication: treatment of adult patients with refractory an aplastic astrocytoma, ...
Alkylating in Biological News
Researchers reveal structure of protein that repairs damage to cancer cells
... strategy to all kinds of other protein-DNA complexes. The AlkB and ABH2 proteins repair alkylation damage to DNA, including the damage caused by alkylating cancer treatments. Alkylation is the addition of certain chemical groups to DNA and is particularly harmful to rapidly growing cells such as ...Alkylating in Biological Technology
Telik Reports Preclinical Results at AACR Annual Meeting
... of TLK58747; Abstract # 4515 Telik researchers identified a novel alkylating agent, TLK58747, which functions as a prodrug, without the need for ... an activation byproduct known to be associated with toxicity of other alkylating agents (acrolein). Key findings: TLK58747 inhibited ...... treatment, never progress beyond the early stages of the disease. About Clearazide Clearazide is a topical form of nitrogen mustard, an alkylating agent that works by inhibiting DNA replication. Nitrogen mustard has also demonstrated activity in other T-cell proliferating diseases such as ...
Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
... to 12:00 p.m. local time on Sunday, April 19, 2009. "The critical role of cleavable linkers for minor groove binding alkylating agent (MGBA) based antibody-drug conjugates" (Abstract #1722), S. Gangwar - Poster presentation from 1:00 to 5:00 p.m. local time on Sunday, April ...Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)
... particularly attractive." About Onrigin Onrigin (laromustine) Injection, formerly known as Cloretazine(R) (VNP40101M), is a novel alkylating agent. Onrigin has been evaluated in over 800 patients in 16 clinical trials to date, including a pivotal Phase II trial in patients sixty years of ...... Medarex's proprietary ADC technology uses a cytotoxic agent that is a potent, synthetically manufactured prodrug (a DNA minor-groove binding alkylating agent) which is attached to an antibody using a stable peptide-based linker. Medarex believes that its ADC technology overcomes many of the key ...
Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting
... cancer therapeutics. Vion has two agents in clinical trials. Onrigin(TM) (laromustine), formerly known as Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...Vion Reports 2008 First Quarter Results
... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...Vion Pharmaceuticals Files Plan With Nasdaq
... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...Vion Reports 2007 Fourth Quarter and Year-End Results
... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. ...
Alkylating in Biological Dictionary
... a free radical, a carbanion or a carbene . alkylating agents are widely used in ... An alkylating antineoplastic agent is an alkylating agent used in cancer treatment that attaches ...
Other ContentsexcavatumpectuspedalpedalpedalpedicleinflammatoryinflammatoryinflammatoryinflammatoryinflammatoryinflammatoryinflammatoryinflammatorypelvispelvispelvispelvisOther TagsContourPeriostealWorstNovusNovusMeridian
(Date:12/14/2009)... Dec. 14 United Dental Care (also known ... the providers of top-notch dental care in Southern California. ... dentistry, kid,s dentistry, braces (orthodontics) and periodontal treatments. ... Dentist offices are staffed with experienced and trusted ... ,, Dr. Eftekhari (Dr. E) is one of these ...
(Date:12/14/2009)... Staff , ... La Jolla, Calif. (Vocus) -- The ... MD, as the new chief of staff of the 372-bed facility. ... team on Jan. 1, 2010. , , , , ,During his ... Scripps La Jolla’s administrative staff and its board of directors. Dr. ...
(Date:12/14/2009)... -- Grubb & Ellis Healthcare REIT II, Inc. announced today ... to stockholders of record as of the close of business ... 2010 and ending on Feb. 28, 2010. The distributions ... year and will be equal to an annualized distribution rate ... share. These distributions will be aggregated and paid in ...
(Date:12/14/2009)... estimated 29,000 future cancers could be linked to scans performed ... Commonly performed CT scans are exposing patients to far more ... tens of thousands of cancers a year, two new studies ... 14/28 issue of the Archives of Internal Medicine , ... Rita F. Redberg, are calling on clinicians to limit radiation ...
(Date:12/14/2009)... highly stigmatized, according to psychiatrists Charles F. Zorumski, ... these Washington University physicians have written a book ... Zorumski and Rubin, who have more than 50 ... patient families, say some of the problems related ... lack of understanding psychiatry and what psychiatrists can ...
Breaking Medicine News(10 mins):Health News:United Dental Care, Gentle Care, Trusted Dentists 2Health News:United Dental Care, Gentle Care, Trusted Dentists 3Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4Health News:Book demystifies psychiatry for the general public 2Health News:Book demystifies psychiatry for the general public 3(Date:12/14/2009)... HOUSTON -- (Dec. 14, 2009) -- Researchers at Rice ... a single nanoparticle that can be tracked in real ... cells, tags them with a fluorescent dye and kills ... the first examples from a growing field called "theranostics" ... treat diseases in a single procedure. , The research ...
(Date:12/14/2009)... and the Biomedical Engineering Society (BMES) have founded a ... CVET ). CVET is a forum ... medical treatment. The first issue of the new ... two other BMES publications at Springer, Annals of ... . , Cardiovascular Engineering and Technology will ...
(Date:12/14/2009)... once thought of tool use as a defining feature of ... other primates, along with birds and an array of other ... Current Biology , a Cell Press publication, adds an ... veined octopus under study manages a behavioral trick that the ... itself over stacked, upright coconut shell "bowls," makes its eight ...
Breaking Biology News(10 mins):Tracking new cancer-killing particles with MRI 2Biomedical Engineering Society's new journal to be published by Springer 2Tool use in an invertebrate: The coconut-carrying octopus 2Swine Flu Infection Rates Continue to Fall 63147 1Swine Flu Infection Rates Continue to Fall 63147 2Swine Flu Infection Rates Continue to Fall 63147 3Abbott Declares 344th Consecutive Quarterly Dividend 63144 1Childrens Hospital Surgeon Receives Prestigious Paul Tessier Medal 63141 1Childrens Hospital Surgeon Receives Prestigious Paul Tessier Medal 63141 2ThinProfileContourTanneSQUEEZESurgiscribeMarkingPeriostealSurgifoamQuickertBeyerWorstBodianNovusMeridian
Other Tagsimplemented 2implemented 3implemented 4implemented 5implemented 6implemented 7implemented 8implemented 9implemented 10metals 2metals 3metals 4concentration 2concentration 3concentration 4concentration 5concentration 6concentration 7concentration 8concentration 9concentration 10practices 2practices 3practices 4practices 5practices 6practices 7practices 8practices 9practices 10rehabilitation 2cardiac 2cardiac 3cardiac 4cardiac 5cardiac 6cardiac 7engineers 2engineers 3engineers 4engineers 5membrane 2membrane 3membrane 4membrane 5membrane 6membrane 7membrane 8membrane 9membrane 10unraveling 2piece 2piece 3piece 4piece 5piece 6piece 7piece 8| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |